| 578. Cost-effectiveness of Infant Vaccination with PCV15 Compared to PCV13 in the United States M Huang, T Hu, J Weaver, K Owusu-Edusei, E Elbasha Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 630, 2022 | | 2022 |
| 989 COST-EFFECTIVENESS OF BOCEPREVIR IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 1 IN SWEDEN J Chhatwal, J Lundberg, S Ferrante, AC El Khourhy, A Oksanen, ... Journal of Hepatology, S386-S387, 2012 | 2 | 2012 |
| A CASE STUDY OF BREAST CANCER TREATMENT DEMONSTRATING THE IMPACT OF TIME DEPENDENT TRANSITION PROBABILITY ADJUSTMENTS ON COMPARATIVE COST EFFECTIVENESS B Jahn, C Kurzthaler, J Chhatwal, E Elbasha, A Conrads-Frank, ... ISPOR Europe 2019, 2019 | | 2019 |
| A dynamic CGE model: An application of R&D-based endogenous growth model theory X Diao, EH Elbasha, TL Roe, AE Yeldan | 29 | 1996 |
| A dynamic transmission model for assessing the impact of pneumococcal vaccination T Malik, K M Bakker, R Oidtman, O Sharomi, G Meleleo, R Nachbar, ... medRxiv, 2024.06. 11.24308671, 2024 | | 2024 |
| A multi-type HPV transmission model EH Elbasha, EJ Dasbach, RP Insinga Bulletin of mathematical biology 70, 2126-2176, 2008 | 84 | 2008 |
| A primer on using mathematics to understand COVID-19 dynamics: Modeling, analysis and simulations AB Gumel, EA Iboi, CN Ngonghala, EH Elbasha Infectious Disease Modelling 6, 148-168, 2021 | 174 | 2021 |
| A146 Abstracts EC Mansley, EH Elbasha, SM Teutsch, ML Berger | | |
| Adding Boceprevir Yields Better Cost-Saving for Chronic Hepatitis C Genotype 1 Treatment in Thailand S Ferrante, EH Elbasha, T Piratvisuth, T Tanwandee, S Lerdlitruangsin, ... Value in Health 17 (7), A677, 2014 | | 2014 |
| Age-based programs for vaccination against HPV EH Elbasha, EJ Dasbach, RP Insinga, RM Haupt, E Barr Value in Health 12 (5), 697-707, 2009 | 42 | 2009 |
| Alternative conversion methods for transition probabilities in state-transition models: validity and impact on comparative effectiveness and cost-effectiveness B Jahn, C Kurzthaler, J Chhatwal, EH Elbasha, A Conrads-Frank, ... Medical Decision Making 39 (5), 509-522, 2019 | 4 | 2019 |
| An economic evaluation of using raltegravir in treatment-experienced HIV-1 infected patients in the UK E Elbasha, W Dunlop, MA Chaudhary, RN Kumar Journal of the International AIDS Society 11 (Suppl 1), P310, 2008 | 1 | 2008 |
| An ex post economic impact assessment of planted forages in West Africa E Elbasha, PK Thornton, G Tarawali ILRI (aka ILCA and ILRAD), 1999 | 100* | 1999 |
| An R&D Model of Endogenous Growth: Calibration, Steady-State and Transition Path Equilibria X Diao, EH Elbasha, T Roe, E Yeldan Department of Economics, Bilkent University, 1996 | | 1996 |
| Analyzing the dynamics of an SIRS vaccination model with waning natural and vaccine-induced immunity EH Elbasha, CN Podder, AB Gumel Nonlinear Analysis: Real World Applications 12 (5), 2692-2705, 2011 | 69 | 2011 |
| Application of Value of Information Analyses in Informing Research Investment Plans for Future Congenital Cytomegalovirus Vaccine Candidates YH Chen, J Cook, A Sinha, M Kaur, EH Elbasha 41st Annual Meeting of the Society for Medical Decision Making, 2019 | | 2019 |
| Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature RP Insinga, EJ Dasbach, EH Elbasha Pharmacoeconomics 23, 1107-1122, 2005 | 252 | 2005 |
| ASSESSMENT OF ECONOMIC EFFICIENCY OF APPLICATION OF RALTEGRAVIR BY PATIENTS WITHOUT EXPERIENCE OF TYPE 1 HIV INFECTION THERAPY IN RUSSIA EH Elbasha, EA Pyadushkina, MV Avxentyeva, AG Tolkushin, MY Frolov FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 8 (2), 43-54, 2015 | | 2015 |
| Assessment of the cost–effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model EJ Dasbach, N Largeron, EH Elbasha Expert Review of Pharmacoeconomics & Outcomes Research 8 (5), 491-500, 2008 | 27 | 2008 |
| Authors’ Reply to Comment on “Risk-Adjusted Performance Measures” EH Elbasha PharmacoEconomics 40 (7), 741-742, 2022 | | 2022 |
Salaheddin MahmudProfessor and Canada Research Chair of Pharmaco-epidemiology, University of Manitoba在 mcgill.ca 的电子邮件经过验证
